Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00919633 | Safety and Efficacy Study to Compare Continuous Infusion of Interferon With Standard of Care for Chronic Hepatitis C | PHASE2 | COMPLETED | 116 | — | — | Jun 1, 2009 | Jul 1, 2012 | Oct 9, 2019 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| Group 1: interferon alfa-2b (dose 1) | EXPERIMENTAL | continuous subcutaneous infusion for 48 weeks |
| Group 2: interferon alfa-2b (dose 2) | EXPERIMENTAL | continuous subcutaneous infusion for 48 weeks |
| Group 3: interferon alfa-2b (dose 3) | EXPERIMENTAL | continuous subcutaneous infusion for 48 weeks |
| Group 4: peginterferon alfa-2b (1.5 μg/kg) | ACTIVE_COMPARATOR | subcutaneous weekly for 48 weeks |
| Name | Type | Description |
|---|---|---|
| interferon alfa-2b | DRUG | subcutaneous continuous infusion at one of three doses for 48 weeks |
| peginterferon alfa-2b | DRUG | 1.5 μg/kg subcutaneous weekly for 48 weeks |
| ribavirin, USP | DRUG | All patients will receive oral ribavirin |
| external drug infusion pump | DEVICE | pump delivery system for continuous subcutaneous infusion of interferon alfa-2b |
Inclusion Criteria: * Signed patient consent form * Genotype 1 chronic HCV with detectable HCV RNA * No previous treatment for HCV infection * Hepatitis B and human immunodeficiency virus negative at screening visit * Able and willing to follow contraception requirements * Screening laboratory valu...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Atea Pharmaceuticals, Inc. | AVIR | 2 | PHASE3 | Bemnifosbuvir-Ruzasvir, Sofosbuvir-Velpatasvir |
| Abbott Laboratories | ABT | 2 | — | Undisclosed |
| AbbVie, Inc. | ABBV | 1 | — | Undisclosed |